The SCCS considers Acetophenone safe, when present as a constituent of natural complex substances that are used in cosmetic products, provided that its concentration does not exceed 100 ppm […]
On May 4th, the FDA posted an FDA Voices blog sharing how FDA is implementing the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) to positively impact public health. […]
On May 1st, CESI published its Spring Newsletter, which features 3 recently updated indicators that provide valuable insight into the state of Canada’s environment. Read on to learn more […]
The final version of the Watch List Approach was published April 28, 2026 on the CEPA Registry. The purpose of the Watch List is to identify substances that have […]
The Canadian Product Safety Pledge, launched Fall 2023 by Health Canada, was created to help protect people in Canada from health and safety risks associated with consumer products and […]
On April 24, 2026, NNHPD updated several health product monographs to include critical safety warnings, most notably regarding peripheral neuropathy risks with Vitamin B6 and increased bleeding risks for […]
PRODUCT APPLICATIONS: Class I Applications: Currently meeting service standards. Class II Applications (meeting Workload Management eligibility criteria): Prioritized Class 2 applications are issued a decision within the […]
The ECHA RAC has officially adopted an opinion to IL1235 20-04-2026 Tonalide – ECHA RAC Opinion as Repr 1B adopted. This is a significant escalation from its previous classification. […]
The SCCS released its preliminary opinion on the safety of Heliotropin (also known as Piperonal) on April 15, 2026. This evaluation was triggered by a proposal to classify the […]
Health Canada’s Explanatory notes for drug establishments on the preparation of a site master file (GUI-0005), published in April 2026, provides a comprehensive framework for manufacturers to document their […]
